New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 21, 2013
08:54 EDTMNKDSummer Street 'much more optimistic' about MannKind approval
After speaking with a former FDA reviewer, Summer Street said it is "much more optimistic" that current trials of MannKind's inhalable insulin for treating type 1 and type 2 diabetes could lead to FDA approval. Summer Street said the consultant it spoke to sees an 85% chance that in the type 1 diabetes study Afrezza hits its endpoint. Shares of MannKind are up 13c to $6.83 in pre-market trading.
News For MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
10:32 EDTMNKDOptions with decreasing implied volatility
Subscribe for More Information
February 25, 2015
05:52 EDTMNKDStocks with implied volatility movement; MNKD NE
Stocks with implied volatility movement; MannKind (MNKD) 79, Noble Corp. (NE) 52 according to iVolatility.
February 24, 2015
16:48 EDTMNKDMannKind reports Q4 EPS (9c), consensus (9c)
Subscribe for More Information
February 23, 2015
15:06 EDTMNKDMannKind volatility increases into Q4 and outlook
MannKind February weekly call option implied volatility is at 103, March is at 63, April is at 60. May is at 55; compared to its 26-week average of 70 according to Track Data, suggests large near term price movement into the expected release into the expected release of Q4 result on February 24.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use